Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
McKinsey
Mallinckrodt
Johnson and Johnson
Express Scripts

Last Updated: November 16, 2019

DrugPatentWatch Database Preview

Upsher Smith Labs Company Profile

See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for UPSHER SMITH LABS, and when can generic versions of UPSHER SMITH LABS drugs launch?

UPSHER SMITH LABS has ninety-five approved drugs.

There are seventeen US patents protecting UPSHER SMITH LABS drugs.

There are sixty-seven patent family members on UPSHER SMITH LABS drugs in seventeen countries and forty-four supplementary protection certificates in nine countries.

Summary for Upsher Smith Labs
International Patents:67
US Patents:17
Tradenames:64
Ingredients:59
NDAs:95

Drugs and US Patents for Upsher Smith Labs

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Upsher Smith Labs ANAGRELIDE HYDROCHLORIDE anagrelide hydrochloride CAPSULE;ORAL 076683-001 Apr 18, 2005 DISCN No No   Start Trial   Start Trial
Upsher Smith Labs CHLORDIAZEPOXIDE HYDROCHLORIDE chlordiazepoxide hydrochloride CAPSULE;ORAL 084041-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Upsher Smith Labs BETHANECHOL CHLORIDE bethanechol chloride TABLET;ORAL 040635-001 Jun 1, 2005 AA RX No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Paragraph IV (Patent) Challenges for UPSHER SMITH LABS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Nasal Spray 200 IU/spray ➤ Subscribe 2006-03-29
➤ Subscribe Extended-release Capsules 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg ➤ Subscribe 2015-12-24

Supplementary Protection Certificates for Upsher Smith Labs Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0253310 SZ 16/1996 Austria   Start Trial PRODUCT NAME: LOSARTAN-KALIUM
0637297 01C0027 France   Start Trial PRODUCT NAME: BEXAROTENE; REGISTRATION NO/DATE: EU/1/01/178/001 20010329
1499331 13C0055 France   Start Trial PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: 434323 20130220
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
McKinsey
Baxter
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.